Brief: Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S.
26/03/2025 11:48
March 26 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS EXPANDS PARTNERSHIP WITH SOBI TO INCLUDE OLEZARSEN COMMERCIALIZATION OUTSIDE THE U.S. Source text: ID:nBw3tcTLca Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors